Pmv Pharmaceuticals Inc (PMVP)
PMV Pharmaceuticals, Inc. is a NASDAQ-listed common stock issue tied to a healthcare company focused on biotechnology and precision oncology. The company works on the discovery and development of small-molecule therapies designed to target p53 mutations and other p53-related cancers in the United States. Its lead program is rezatapopt, described as a selective structural corrector for p53 Y220C mutations and currently in Phase 2 clinical trials for tumor-agnostic diseases. The company was founded in 2013, was previously known as PJ Pharmaceuticals, Inc., and adopted its current name in July 2013. PMV Pharmaceuticals is headquartered in Princeton, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PMVP
|
$1.91
|
26.7% Upside
|
Undervalued
|
$4.20
|
178.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
1.6x
|
114 M
|
32.168 M
|
0.2%
|
81.0%
|
-3.9
|
94.8%
|
